Andreas Johne

6.6k citations

85 papers · 4.2k indexed · 1 hit paper · h-index 23

Impact in

Pharmacology top 0.1%
- Pharmacogenetics and Drug Metabolism
Transplantation top 1%
- Renal Transplantation Outcomes and Treatments

Papers in

Hepatology 21
- Liver physiology and pathology 18
- Hepatocellular Carcinoma Treatment and Prognosis 11
Oncology 43
- Pancreatic and Hepatic Oncology Research 13
- Colorectal Cancer Treatments and Studies 10
- Lung Cancer Research Studies 10
- Drug Transport and Resistance Mechanisms 9

Co-authors: Ivar Roots Thomas Gerloff Ingolf Cascorbi Sven Hoffmeyer Ulrich Brinkmann J. Brockmöller Oliver von Richter Oliver Burk
Journals: Journal of Clinical Oncology (14 papers)Annals of Oncology (13 papers)Clinical Pharmacology & Therapeutics (5 papers)Journal of Thoracic Oncology (4 papers)British Journal of Clinical Pharmacology (4 papers)
Partner nations: Germany United States Taiwan

In The Last Decade

Andreas Johne

84 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo 2000 · 2.0k citations

Peers

Countries citing papers authored by Andreas Johne

Since Specialization

Citations

This map shows the geographic impact of Andreas Johne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Johne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Johne more than expected).

Fields of papers citing papers by Andreas Johne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Johne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Johne. The network helps show where Andreas Johne may publish in the future.

Co-authors

The 25 scholars most cited alongside Andreas Johne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andreas Johne Line = papers co-authored together Andreas Johne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib Clinical Cancer Research ·Christian Rolfo, Aurora O’Brate, Dipti Parab, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh, Andreas Johne, Paul K. Paik	2025	1
2	Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence JCO Precision Oncology ·THELMA, Hongming Pan, Jean Frédéric Blanc, Véronique Grando, Ho Yeong Lim, Ramasini Bruna, Aurora O’Brate, Christopher Stroh, Manja Friese‐Hamim, Joachim Albers, Andreas Johne, Sandrine Faivre	2024	6
3	Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial. Journal of Clinical Oncology ·Niels Reinmuth, Julien Mazières, Sanjay Popat, Luis Paz‐Ares, Junmin Zhan, Anthony J. Hatswell, Soetkin Vlassak, Andreas Johne, غلامحسین معماریان, Paul K. Paik	2024	1
4	Explainable machine learning prediction of edema adverse events in patients treated with tepotinib Clinical and Translational Science ·Federico Amato, Rainer Strotmann, Roberto Castello, Rolf Bruns, Lian Fitriyani, Andreas Johne, Karin Berghoff, Karthik Venkatakrishnan, Nadia Terranova	2024	2
5	1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial Annals of Oncology ·Santiago Viteri, Enriqueta Felip, Frank Griesinger, Marina Chiara Garassino, Hiroshi Sakai, Xiuning Le, Rémi Veillon, Egbert F. Smit, Jo Raskin, Michael Thomas, M-J. Ahn, Soetkin Vlassak, Rolf Bruns, Andreas Johne, Paul K. Paik	2023	3
6	Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis Clinical Cancer Research ·Chong Kin Liam, Duane H. Jaecks, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, M. Hofmann, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu	2023	22
7	The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations Molecular Cancer Therapeutics ·Joachim Albers, Manja Friese‐Hamim, Nils Demary, Oliver Schadt, Asoka Gunaratne, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat	2023	10
8	Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification. Journal of Clinical Oncology ·Alex B. Ryder, Kouji Lida, Emmanuelle Boutmy, Yuexi Wang, Antonio DeJesus Cruz, Christopher Stroh, Andreas Johne	2023	0
9	1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib Annals of Oncology ·Christian Rolfo, T Ozyński, C Menzel, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh, Andreas Johne, Paul K. Paik	2023	3
10	Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations Cancer Chemotherapy and Pharmacology ·S. Gara, Kathrine Roy, Joakim Nyberg, Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, Rainer Strotmann	2022	8
11	584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours Annals of Oncology ·Paul K. Paik, S. Gara, G. Fontana, S. Ye, Orestis Papasouliotis, Richard Anziano, Karin Berghoff, Andreas Johne, Pascal Girard, Rainer Strotmann	2020	5
12	399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations Annals of Oncology ·Marisa A. Bittoni, James Chih‐Hsin Yang, Qingqing Lang, Nir Peled, Egbert F. Smit, D. Ross Camidge, David P. Carbone, Kouji Lida, Emmanuelle Boutmy, Andreas Johne, Paul K. Paik	2020	2
13	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors Clinical Cancer Research ·Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, S. Gara, Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese‐Hamim, Pascal Girard, Samer El Bawab, David S. Hong	2019	67
14	Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data Annals of Oncology ·Yi‐Long Wu, Jianya Zhou, Shun Lü, Y. Zhang, Jun Zhao, Hongming Pan, Yaow-Ming Chen, Chih‐Feng Chian, Rolf Bruns, Andreas Johne, J. Scheele, Ying Cheng	2018	2
15	Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects Clinical Pharmacology in Drug Development ·Yi Ying Ng, Andreas Johne, Achim Freisleben, Nwankwo Malarchy Ekwunife, Veprentsev, Sonja Krösser	2013	15
16	An Anomalous Haplotype Distribution of the Arrestin Domain–Containing 4 Gene ( ARRDC4 ) Haplotypes in Caucasians Genetic Testing ·Gun Hwa Lee, Mark Goldammer, Laís Salgueiro Garcez, Lee A. Ritscher, Andreas Johne, P.M. Mrozikiewicz, Ivar Roots, Karla Köpke	2008	2
17	Influence of the SLCO1B11b and 5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels Naunyn-Schmiedeberg s Archives of Pharmacology ·Thomas Gerloff, 閔賢淑, Jessica Mwinyi, Andreas Johne, Thomas Sudhop, Dieter Lütjohann, Ivar Roots, Klaus von Bergmann	2006	22
18	Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients British Journal of Clinical Pharmacology ·Steffen Bauer, Elke Störmer, Andreas Johne, H. Krüger, Klemens Budde, H.-H. Neumayer, Ivar Roots, Ingrid Mai	2003	128
19	MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males British Journal of Clinical Pharmacology ·Thomas Gerloff, 閔賢淑, Andreas Johne, Kersti Oselin, Christian Meisel, Ingolf Cascorbi, Ivar Roots	2002	124
20	Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin International Journal of Clinical Pharmacology and Therapeutics ·Ingrid Mai, H. Krüger, Klemens Budde, Andreas Johne, J. Brockmöller, H.-H. Neumayer, Ivar Roots	2000	83

About Andreas Johne

Andreas Johne is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Pharmacology, having authored 85 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (38 papers), Liver physiology and pathology (18 papers), Lung Cancer Diagnosis and Treatment (14 papers), Pancreatic and Hepatic Oncology Research (13 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Research Studies (10 papers) and Drug Transport and Resistance Mechanisms (9 papers). The work is most often cited by research in Pharmacology (1.1k citations), Transplantation (279 citations), Oncology (2.4k citations), Pediatrics, Perinatology and Child Health (1.5k citations) and Complementary and alternative medicine (399 citations). Andreas Johne has collaborated with scholars based in Germany, United States and Taiwan. Frequent co-authors include Ivar Roots, Thomas Gerloff, Ingolf Cascorbi, Sven Hoffmeyer, Ulrich Brinkmann, J. Brockmöller, Oliver von Richter, Oliver Burk, Michel Eichelbaum and Ingrid Mai. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Pharmacology & Therapeutics, Journal of Thoracic Oncology and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact